Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
|Autoři||PAVLÍK Tomáš — JANOUŠOVÁ Eva — POSPÍŠIL Zdeněk — MUŽÍK Jan — ŽÁČKOVÁ Daniela — RÁČIL Zdeněk — KLAMOVÁ Hana — CETKOVSKÝ Petr — TRNĚNÝ Marek — MAYER Jiří — DUŠEK Ladislav|
|Druh||Článek v odborném periodiku|
|Citace||PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Zdeněk POSPÍŠIL, Jan MUŽÍK, Daniela ŽÁČKOVÁ, Zdeněk RÁČIL, Hana KLAMOVÁ, Petr CETKOVSKÝ, Marek TRNĚNÝ, Jiří MAYER a Ladislav DUŠEK. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. BMC Medical Research Methodology, 2011, roč. 11, č. 140, s. 1-12. ISSN 1471-2288. doi:10.1186/1471-2288-11-140.|
|Obor||Onkologie a hematologie|
|Klíčová slova||chronic myeloid leukaemia; treatment; statistical methods|
The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML patients can experience multiple leukaemia-free periods during the course of their treatment. Traditional measures of treatment efficacy such as leukaemia-free survival and cumulative incidence are unable to cope with multiple events in time, e.g. disease remissions or progressions, and as such are inappropriate for the efficacy assessment of the recent CML treatment. The results have shown a difference between the estimates of the current cumulative incidence function and the common cumulative incidence of leukaemia-free patients, as well as between the estimates of the current leukaemia-free survival and the common leukaemia-free survival. Regarding the currently available follow-up period, both differences have reached the maximum (12.8% and 20.8%, respectively) at 3 years after the start of follow-up.
- Související projekty: